ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2017

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.

Pedro Mezquita-Raya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.